Arrow Mark Colorado Holdings LLC Erasca, Inc. Transaction History

Arrow Mark Colorado Holdings LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$2.74 - $4.44 $2.52 Million - $4.08 Million	-918,815 Reduced 79.74%	233,400 $702,000
Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $96,308 - $212,176	24,758 Added 2.2%	1,152,215 $4.97 Million
Q3 2022 Nov 14, 2022	BUY	$5.82 - $10.68 $2.96 Million - $5.43 Million	508,260 Added 82.08%	1,127,457 $8.79 Million
Q2 2022 Aug 15, 2022	BUY	$4.58 - $8.72 $456,172 - $868,520	99,601 Added 19.17%	619,197 $3.45 Million
Q1 2022 May 16, 2022	BUY	$8.6 - $15.48 $230,480 - $414,864	26,800 Added 5.44%	519,596 $4.47 Million
Q4 2021 Feb 14, 2022	BUY	$12.51 - $22.75 $207,065 - $376,558	16,552 Added 3.48%	492,796 $7.68 Million
Q3 2021 Nov 15, 2021	BUY	$17.43 - $24.34 $8.3 Million - $11.6 Million	476,244 New	476,244 $10.1 Million

140

229M

28.7K

117K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $289M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Arrow Mark Colorado Holdings LLC, based on Form 13F filings with the SEC.

Stay updated on Arrow Mark Colorado Holdings LLC with notifications on news.